Merck & Co. Inc. closed 29.03% below its 52-week high of $134.63, which the company reached on June 25th.

The pharmaceutical industry could generate more than $1.2 trillion in global sales in 2025, according to Statista. The cancer segment alone is expected to generate $208 billion in sales this year. The ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Needham initiated a Buy rating for Absci (ABSI), noting its AI-powered drug discovery platforms, strategic partnerships, and ...

Shares of Summit Therapeutics ( SMMT 4.80%) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 472.57% and ...

Merck & Co Inc (MRK) stock saw a decline, ending the day at $96.24 which represents a decrease of $-1.68 or -1.72% from the prior close of $97.92. The stock opened at $98.08 and touched a low of ...